Clinical Trials Logo

MERS clinical trials

View clinical trials related to MERS.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04130594 Recruiting - Clinical trials for MERS (Middle East Respiratory Syndrome)

Study of Safety and Immunogenicity of BVRS-GamVac

Start date: November 7, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

The Middle East respiratory syndrome coronavirus (MERS-CoV) was identified in 2012 during the first Middle East respiratory syndrome (MERS) outbreak. MERS-CoV causes an acute lower-respiratory infection in humans, with a fatality rate of ~34.5%. The aim of the study is to assess the safety and immunogenicity of adenoviral-based vaccine against MERS - BVRS-GamVac.

NCT ID: NCT04128059 Recruiting - Clinical trials for MERS (Middle East Respiratory Syndrome)

Study of Safety and Immunogenicity of BVRS-GamVac-Combi

Start date: November 6, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

The Middle East respiratory syndrome coronavirus (MERS-CoV) was identified in 2012 during the first Middle East respiratory syndrome (MERS) outbreak. MERS-CoV causes an acute lower-respiratory infection in humans, with a fatality rate of ~34.5%. The aim of the study is to assess the safety and immunogenicity of heterologous adenoviral-based vaccine against MERS - BVRS-GamVac-Combi.